Locoregionally advanced nasopharyngeal carcinoma (stage III to IVA): lines of therapy
5 standard-of-care settings across 3 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
Screening, prevention and diagnosis
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Staging | MRI of the nasopharynx and neck, PET-CT or CT of chest and abdomen with bone scan, plasma EBV DNA, dental and audiological assessment. | CSCO/ASCO guideline on nasopharyngeal carcinoma 2021; NCCN Head and Neck Cancers | 92 |
Locally advanced
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Stage III to IVA, standard | Induction gemcitabine and cisplatin for three cycles followed by intensity-modulated radiotherapy (70 Gy) with concurrent cisplatin; TPF induction as an alternative. | CSCO/ASCO guideline on nasopharyngeal carcinoma 2021; NCCN Head and Neck Cancers | 93 |
Other settings
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | After chemoradiotherapy | Metronomic capecitabine for one year in high-risk patients; EBV DNA-directed adjuvant therapy in trials (NRG-HN001). | CSCO/ASCO guideline on nasopharyngeal carcinoma 2021; NCCN Head and Neck Cancers | 82 | |
| All comers | Immunotherapy in the curative setting | PD-1 antibody (sintilimab in CONTINUUM; toripalimab and camrelizumab in trials) added to induction and chemoradiotherapy in high-risk disease, adopted in China. | CSCO/ASCO guideline on nasopharyngeal carcinoma 2021; NCCN Head and Neck Cancers | 99 | |
| All comers | Follow-up | Plasma EBV DNA, MRI and nasopharyngoscopy; management of xerostomia, hearing loss, hypothyroidism and hypopituitarism. | CSCO/ASCO guideline on nasopharyngeal carcinoma 2021; NCCN Head and Neck Cancers | 40 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.